PubMed Health⌕ Search

Biomedical subjects

S Jelić

Publications and source records attributed to S Jelić.

At least 91 records · Page 5Linked to original sources
PubMedDate not supplied

[Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].

Dose-intensity is an amount of drug delivered per unit of time, expressed as mg/m2/week, regardless of the schedule or route of administration. Relative dose intensity is an amount of drug delivered per unit of time relative to an arbitrary chosen standard single drug or, in a combination regimen, the decimal fraction of the ratio of the average dose-intensity of all drugs of the test regimen compared to the standard regimen. Calculations can be made with intended (planned) dose intensity or actual or received dose intensity. A positive effect of dose intensity on outcome (response rate) has been demonstrated in advanced ovarian, colon, breast cancers and lymphomas. Small-cell lung cancer (SCLC) is very responsive to chemotherapy, although in the majority of patients conventional-dose chemotherapy is not effective in meaningfully prolonging median survival. Randomized studies suggest that a dose may be important for the success of chemotherapy in SCLC. The aim of the present study was to investigate the relation between dose-intensity and tumour objective response in a group of patients with SCLC treated with two cysplatin-based regimens. Fifty patients were randomized to receive 60 mg/m2 of a cysplatin and 120 mg/m2 of etoposide on days 1, 3 and 5 (Group A), or the same dose of cysplatin and 120 mg/m2 of epirubicin (Group B). The intercylce interval was 4 weeks, and 6 cycles were planned. The planned dose-intensity of cysplatin was calculated as 15 mg/m2/wk. However, the actual or received dose-intensity of cysplatin was 12.55 +/- 1.7 mg/m2/wk and 13.62 +/- 3.1 mg/m2/wk in Group A and Group B of patients, respectively. In other words, in the combination with etoposide, 83.7% of the planned dose of cysplatin has been delivered, while in the combination with epirubicin the cysplatin dose-intensity was 90.8%. The received dose-intensity of etoposide was calculated as 77.7% (planned dose intensity was 90 mg/m2/wk and actual dose-intensity 70 mg/m2/wk). Similarly, the received dose intensity of epirubicin was found to be 82.3% (30 mg/m2/wk planned and 24.4 mg/m2/wk actual). The average dose intensity in Group A was found to be 80.72% and in Group B 86.04%. Compared to patients with stable and progressive disease, the patients obtained objective tumour response received 5% and 10% higher relative dose intensity of cysplatin in Group A and Group B, respectively. Relative dose intensity of etoposide and epirubicin were similar in patients with or without objective tumour response. In conclusion, a positive relation between cysplatin dose intensity and objective tumour response was demonstrated. A higher relative dose intensity of cysplatin could be reached in combination with epirubicin compared to combination with etoposide.

Aged↗
PubMedDate not supplied

General principles of chemotherapy.

Chemotherapy relatively recently became an available tool for treating cancer. It is now used at some time during the course of the disease of most patients either for cures for palliative reasons. Approximately two-thirds of cancer patients will develop recurrent of disseminated neoplastic disease and become candidates for systemic treatment.

Antineoplastic Agents↗
PubMedDate not supplied

Pretreatment determination of isohaemagglutinin titter values in patients with malignant lymphomas and metastatic solid tumors.

Isohaemagglutinin synthesis starts 2-4 months after birth, growing progressively and reaching adult values at the age of 5-10 years. Isohaemagglutinin concentration decreases with age. Isohaemagglutinins are mostly immunoglobulins belonging to the class IgM, but also IgA and IgG. Agglutination titter shows correlation with the total concentration of those three immunoglobulin isotypes. For the time being there are few data on the isohaemagglutinin titter level in various diseases. Purpose of this work is to determine whether there are any isohaemagglutinin titter alterations in patients with neoplasia. Isohaemagglutinin titter was investigated in 177 patients treated at the Institute of Oncology and Radiology and 340 blood donors. Out of 177 patients, 31 had Hodgkin's lymphoma (HL), 89 had non-Hodgkin Lymphoma (NHL) and 57 had metastatic solid tumors (MST). Statistical evaluation included Kruskal-Wallis and Mann-Whitney tests. In all groups of patients isohaemagglutinin titters were considerably lower as compared with the healthy population (p < 1 x 10e-5). There was a significant difference in titter values (p = 0.003) between O blood group patients with NHL where anti-A1 titter was significantly lower (Med = 8; range: 1-256) compared with anti-A1 titter in patients with O blood group suffering from MST (Med = 16; range: 2-64). Anti-B titter in the same groups of patients also showed lower values (p = 0.042); in NHL anti-B titter values was Med = 4, range: 1-32 vs Med = 8, range: 1-64 in MST. In the group of patients with HL, A blood group was far more frequent (17/31) compared with the group with MST (22/57) (p = 0.02). Pretherapy determination of isohaemagglutinin titter in patients with malignant diseases shows that it is significantly lower than the titter in healthy population. Abnormally low isohaemagglutinin titter value irrespective of the type and site of the malignant tumor, points to insufficiency of the IgM-related humoral immune response, to malignancy as a systemic disease, and places isohaemagglutinins among biological markers.

ABO Blood-Group System↗
PubMedDate not supplied

Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.

From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females. In 3 patients an urgent laparotomy without previous diagnostic procedures was performed, while 4 patients had laparotomy only after radiographic and endoscopic diagnosis of a tumor. Six patients had radical surgery and 1 palliative only. Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic). By further investigation, in 2 cases with localization within transversal part of colon and rectum no other sites of NHL were found. They are under regular controls with 45+ and 45+ months disease free survival. Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization. Both patients had early death from lymphoma. The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months. Since the median survival in our group of patients is at the moment 41+ months and the median has not yet been reached, our experience does not confirm literature data claiming bad prognosis of primary NHL of the colon and rectum. A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.

Adult↗
PubMedDate not supplied

High-dose anthracyclines in the treatment of advanced primitive neuroectodermal tumors in adults--a single institution experience.

Primitive neuroectodermal tumors (PNET) are rare malignancies of presumed neural crest origin, most often presenting as bone or soft tissue masses in the trunk or axial skeleton, in children and young adults. Treatment of advanced PNET in adults is not clearly defined in the literature. Data concerning dose-intensive chemotherapy regimens for poor-risk patients with those tumors are sparse, due to rarity of PNET in adults, their diverse presentation, the variable treatment procedures applied and the absence of direct comparisons. On the other hand, the role of anthracyclines in the treatment of advanced soft tissue sarcomas is well known and substantial. Six advanced PNET patients were treated at the Institute for Oncology and Radiology of Serbia, during last five years, with high-doses of doxorubicin or epidoxorubicin combined with cisplatin. The paper reviews each of our patients, discussing how does chemotherapy influence the outcome in these patients, in context of the feasibility of high-doses of anthracyclines in advanced settings. High dose anthracyclines (epidoxorubicin 150 mg/m2) in combination with cisplatin 120 mg/m2 induced a complete response lasting for 63+ months in a patient with desmoplastic medulloblastoma of the cerebellum metastatic to bones and bone marrow. The same treatment but with the epidoxorubicin dose of 180 mg/m2 induced a complete response in a patient with olfactory neuroblastoma. Administration of high dose Doxorubicin (75 mg/m2) seems feasible in association with irradiation treatment in patients with extraosseal Ewing sarcoma/PNET but the place of high dose chemotherapy within this setting remains to be determined.

Adult↗